Outcomes after therapy with DNA-damaging agents such as irinotecan or oxaliplatin have been seen to improve in patients with homologous recombination-deficient colorectal cancer (HRD CRC) compared to those who have HR proficient CRC (HRP CRC).
Upregulation of C-X-C motif chemokine ligand 1 (CXCL1) has been validated in patients with colorectal cancer (CRC), but the mechanism behind CXCL1 affecting CRC tumor cell progression is not clear. Gene-editing techniques were used to investigate the impact of CXCL1 knockout and overexpression in CRC cells.
Previous studies have demonstrated that increased expression of the granulocyte-macrophage colony-stimulating factor (GM-CSF) correlated with poor prognosis in patients with cholangiocarcinoma (CCA) and pancreatic ductal adenocarcinoma (PDAC). In the current study, a research team at the University of Rochester Medical Center aimed to assess the impact of blocking GM-CSFR signaling in CCA and PDAC.
Cholangiocarcinoma (CCA) is a lethal hepatobiliary cancer with poor outcome; thus, new therapeutic approaches are needed. It is known that tyrosine-protein kinase LCK activates Yes-associated protein (YAP), which is a well-known known oncogene in CCA. Researchers have hypothesized LCK as a potential therapeutic target in CCA.
While fecal immunochemical tests (FIT) are common strategies for colorectal cancer (CRC) screening, the potential use of blood-based biomarkers could provide an alternative method to increase compliance in population-based screening programs for early detection of CRC. Researchers from EDP Biotech Corp. aimed to identify novel blood-based biomarker candidates for use in CRC screening.
At the recent 2023 ASCO GI Cancers Symposium, researchers from the Royal College of Surgeons in Ireland (RCSI) presented results of a preclinical study that aimed to evaluate the potential of administering the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor ribociclib with the phosphoinositide 3-kinase (PI3K) inhibitor alpelisib.